Michel Gillard is a Fellow & Senior Director of CNS Biology at UCB Pharma, where he leads Neuroscience Discovery. His work focuses on in vitro pharmacology for CNS drug development, informed by his PhD from the Université libre de Bruxelles. He is a prolific author, particularly in the field of epilepsy research.
Michel played a pivotal role in identifying and characterizing the Synaptic Vesicle protein 2A (SV2A) as the molecular target for the successful antiepileptic drug levetiracetam.
Michel Gillard
Fellow & Senior Director, CNS Biology at UCB Pharma
Brussels Metropolitan Area, Belgium
Overview
Topics They Care About
Antiepileptic Drug Discovery
He has extensively published research on the discovery and mechanisms of antiepileptic drugs, including levetiracetam and brivaracetam.
CNS Target Validation
His research focuses on identifying and validating novel molecular targets within the central nervous system, such as the SV2A protein and orphan GPCRs like GPR17.
GPCR Pharmacology
Actively researches G protein-coupled receptors as therapeutic targets and seeks to hire talent in this specific field for his department at UCB.
Media Appearances
Michel has no verified media appearances
Work History
1989
Fellow & Senior Director, CNS Biology at UCB Pharma
Education
Education details unavailable from PhD
Education details unavailable from Université libre de Bruxelles
More Information
Social Presence :
Prographics :
Exp : 37
Location : Brussels Metropolitan Area, Belgium
Job Level : Senior
Designation : Fellow & Senior Director, CNS Biology at UCB Pharma
